Jushi Q3 Revenue Up 7% to $70.5M; Net Loss Narrows to $12.5M
JUSH sits 51% above its 52-week low of $0.34 on light trading volume (0.1× avg).
Summary
Jushi reported Q3 2026 revenue of $70.5 million, up 7% year-over-year, with the net loss narrowing to $12.5 million and Adjusted EBITDA of $13.6 million. Cash of $30.9 million against $215.6 million of gross debt keeps financing risk front and center as the company prepares for Virginia adult-use sales.
Key Events · Earnings and Guidance · JUSH
-
Q3 Revenue Grows 7% to $70.5M
Revenue rose to $70.5 million from $65.7 million a year earlier, with retail up 3.5% to $60.8 million and wholesale up 40% to a record $9.7 million.
-
Net Loss Narrows to $12.5M
Net loss fell from $23.7 million in Q3 2025, helped by a $0.2 million derivative fair-value gain versus a $6.3 million loss a year ago; Adjusted EBITDA was $13.6 million at a 19.3% margin.
-
Debt Load Dominates Balance Sheet
Cash, equivalents and restricted cash totaled $30.9 million against $215.6 million of gross debt subject to scheduled repayments, with $32.4 million of debt classified as current.
-
Virginia Adult-Use Financing Planned
Management said it is exploring financing alternatives to fund cultivation and processing investments ahead of Virginia adult-use sales scheduled to begin July 1, 2027.
Analysis · JUSH · Life Sciences
The core business is stabilizing: revenue grew 7% to $70.5 million, and wholesale delivered a record $9.7 million quarter. The net loss more than halved to $12.5 million from $23.7 million a year ago, largely because derivative fair-value swings flipped to a small gain. Adjusted EBITDA of $13.6 million was essentially flat year-over-year, so the improvement owes more to below-the-line items than to operating leverage. The balance sheet remains the real constraint: $30.9 million of cash against $215.6 million of gross debt subject to scheduled repayments, with $32.4 million of that debt now classified as current. Management explicitly says it is exploring financing alternatives for Virginia adult-use buildout ahead of the July 1, 2027 start date, which points to potential future dilution or new debt.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUSH was trading at $0.52 on OTC in the Life Sciences sector, with a market capitalization of approximately $102.8M. The 52-week trading range was $0.34 to $0.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.